ArticleClinical rheumatology2025
Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAxial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are chronic inflammatory diseases that often cause joint damage, potentially leading to joint replacement surgery. We assessed whether Janus kinase (JAK) inhibitors reduce the risk of total knee or hip replacement compared to nonsteroidal anti-inflammatory drugs (NSAIDs).
methodsUsing the Merative™ MarketScan® Commercial Database, we conducted a nested case-control study of adults aged 18-65 years with axSpA and/or PsA from October 2015 to December 2021. Medication exposure was categorized hierarchically using pharmacy and procedure claims, including JAK inhibitors, non-tumor necrosis factor inhibitor biologics (non-TNFi biologics), TNF inhibitors (TNFi), DMARDs, NSAIDs (referent), and none. Logistic regression with confounder adjustment assessed associations between medication class and joint replacement risk.
resultsAmong 8855 eligible adults, 1771 cases of joint replacement were identified. JAK inhibitor use was not significantly associated with reduced odds of joint replacement compared to NSAIDs (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.41-1.08). Non-TNFi biologic users (OR 0.66, 95% CI 0.53-0.82), TNFi users (OR 0.63, 95% CI 0.52-0.76), and DMARD users (OR 0.65, 95% CI 0.53-0.80) had lower odds of joint replacement than NSAID users.
conclusionWe did not find conclusive evidence that relative to NSAIDs, JAK inhibitors prevent end-stage arthritis requiring surgery in axSpA and PsA; however, risk was reduced with use of non-TNFi biologics, TNFi, or DMARDs. Longer-term data are needed to understand the optimal utilization of JAK inhibitors in preventing end-stage arthritis in these conditions. Key Points • Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are chronic inflammatory diseases that often cause joint damage, potentially leading to joint replacement surgery. • In our study, although there was not conclusive evidence that JAK inhibitors prevent end-stage arthritis requiring surgery in axSpA and PsA relative to NSAIDs, we did find that risk was reduced with use of non-TNFi biologics, TNFi, or DMARDs. • Understanding the impacts of different medication classes, including Janus kinase (JAK) inhibitors and tumor necrosis factor inhibitors (TNFi) relative to nonsteroidal anti-inflammatory drugs (NSAIDs) may guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.